STELLAR BANCORP INC STEL 深 沪
已收盘 10-31 16:00:00 美东时间
29.43
-0.070
-0.24%
华盛通- 最 高29.73
- 今 开29.25
- 成交量 25.65万股
- 最 低 29.03
- 昨 收 29.50
- 总市值 15.15亿
- 52周最高 32.24
- 市盈率 静 13.69
- 换手率 0.50%
- 52周最低 23.845
- 委 比 0.00%
- 总股本 5147.32万
- 历史最高 35.30
- 量 比 1.34
- 振 幅 2.37%
- 历史最低 9.59
- 每 手 1
- 风险率 1.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 买入！Fermi、Neptune获多家大行首予评级；伯克希尔哈撒韦罕见地获得“卖出”评级；摩根大通上调苹果目标价升至290美元
今日重点评级关注：Guggenheim：上调Neumora Therapeutics评级至"买入"，目标价14美元；韦德布什：上调Fate Therapeutics评级至"跑赢大市"，目标价从5美元升至7美元
10-28 10:08
FDA Expands Approval of Merck's WINREVAIR After Study Shows 76% Drop in PAH Death and Hospitalization Risk
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an update to the U.S. product label based on the Phase 3 ZENITH trial for
10-27 18:47
Jindal Steel Limited Schedules Q2FY26 Earnings Conference Call
Jindal Steel & Power Ltd. ( ($IN:JINDALSTEL) ) has issued an announcement. ...
10-25 01:22
Stellar Bancorp Q3 EPS $0.50 Beats $0.49 Estimate, Sales $105.630M Miss $105.918M Estimate
Stellar Bancorp (NYSE:STEL) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.49 by 2.04 percent. This is a 20.63 percent decrease over earnings of $0.63 per share from the
10-24 19:01
Earnings Scheduled For October 24, 2025
Companies Reporting Before The Bell • Eni (NYSE:E) is expected to report quarte...
10-24 16:32
Jindal Steel Initiates Postal Ballot for Remote E-Voting
An update from Jindal Steel & Power Ltd. ( ($IN:JINDALSTEL) ) is now availa...
10-24 01:16
Earnings Outlook For Stellar Bancorp
Stellar Bancorp (NYSE:STEL) is set to give its latest quarterly earnings report...
10-23 23:02
华尔街顶级分析师最新评级报告：高盛遭下调，Coinbase获初始覆盖
华尔街最受关注、且能影响市场走势的研究评级报告现已汇总于此。以下是由《The Fly》整理的今日投资者需重点关注的评级动态。 五家获上调评级的公司： 雷...
10-21 21:55
Exelixis Phase 3 STELLAR-303: Zanzalintinib Plus Atezolizumab Extends Survival To 10.9 Months In Metastatic Colorectal Cancer
– Zanzalintinib in combination with atezolizumab improved median overall survival to 10.9 months versus 9.4 months with regorafenib, and significantly reduced the risk of death by 20% in the intention-to-treat population
10-20 14:45
Jindal Steel Odisha Limited’s Credit Rating Upgraded
An announcement from Jindal Steel & Power Ltd. ( ($IN:JINDALSTEL) ) is now ...
10-11 02:23
